TauRx’s late-stage clinical trial reaches new milestone
TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer’s Disease (AD) research, has announced that the last patient has completed treatment in the blinded phase of their late-stage phase three clinical trial, Lucidity.This significant milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine top line results on the safety and efficacy of Hydromethylthionine mesylate (which TauRx refers to under the chemical abbreviation, HMTM). The top line results are due to be announced in May.
Professor Claude Wischik, Executive